COR803 is a novel small molecule 3CLpro inhibitor discovered and developed by Cortexyme based on its expertise in cysteine protease inhibition.
It is only the second healthcare provider in the world to attain the Stage 6 DIAM certification.
With $120m jointly invested in the newly-formed initiative, and with other strategic investors expected to join, the venture will develop an alternative, plant-based ingredient using biotechnology
Revenues from operations for the full year ended March 31, 2022 stood at Rs. 590.05 crore as compared to Rs. 449.82 crore in FY21
63-year old woman gets rare Transcatheter Tricuspid Valve Replacement (TTVR)
Apollo Hospitals Chennai is the first healthcare institution in South India to use this protected TAVI / TAVR technology.
The Ayushman Bharat Digital Mission (ABDM) aims to replicate this success in healthcare delivery by building an equitable, accessible and inclusive ecosystem
Becomes the first airline globally to develop and launch sustainable, temperature-controlled containers for the transportation of pharmaceuticals
Bayer now present in four of the largest biotechnology hubs in the United States
TLANDO was approved by the U.S. Food and Drug Administration (FDA) on March 28, 2022.
Subscribe To Our Newsletter & Stay Updated
